TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
PLYMOUTH, MN, April 19, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that it will release its financial results for the first quarter 2017 after the close of trading on Wednesday, May 3, 2017. The Company’s management team will host a corresponding conference call beginning at 3:30pm CT/4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 930-5751 for domestic callers or (253) 336-7277 for international callers, using Conference ID: 97479321. To listen to a live webcast, please visit the investor relations section of the Entellus Medical website at: www.entellusmedical.com.
The webcast replay will be available on the Entellus Medical website following the completion of the call.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of patients. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus Medical platform of products provides effective and easy-to-use solutions intended to help simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s core product lines, XprESS™ ENT Dilation System, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify treatment based in the operating room. Entellus Medical is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
